Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine …
subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine …
[HTML][HTML] Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
GM O'Kane, TA Barnes, NB Leighl - Current Oncology, 2018 - ncbi.nlm.nih.gov
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (nsclc s) that benefit from precision medicine. First …
subgroup of non-small-cell lung cancers (nsclc s) that benefit from precision medicine. First …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
GM O'Kane, TA Barnes, NB Leighl - Current Oncology, 2018 - search.ebscohost.com
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First …
subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
GM O'Kane, TA Barnes… - … oncology (Toronto, Ont …, 2018 - pubmed.ncbi.nlm.nih.gov
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First …
subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
GM O'Kane, TA Barnes, NB Leighl - Current Oncology (Toronto, Ont …, 2018 - europepmc.org
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (nsclc s) that benefit from precision medicine. First …
subgroup of non-small-cell lung cancers (nsclc s) that benefit from precision medicine. First …
[PDF][PDF] Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
GM O'Kane, TA Barnes, NB Leighl - Curr Oncol, 2018 - pdfs.semanticscholar.org
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First …
subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First …